• Synergistic Suppression of Pancreatic EMT via CDK4/6 and BET

  2026-06-09

  Gu et al. (2025) reveal that combining CDK4/6 and BET inhibition in pancreatic ductal adenocarcinoma (PDAC) models not only suppresses tumor growth but also reverses epithelial-to-mesenchymal transition (EMT) by regulating GSK3β-mediated Wnt/β-catenin and TGF-β/Smad signaling. The study's mechanistic insights provide a strong rationale for targeting convergent pathways in aggressive cancers and inform preclinical strategy development.

• Ellagic Acid: Precision CK2 Inhibition in Cancer Biology Res

  2026-06-09

  Ellagic acid (2,3,7,8-tetrahydroxychromeno chromene dione) offers unmatched selectivity and potency for dissecting CK2-driven pathways in cancer and senescence models. This guide unpacks advanced workflows, troubleshooting, and experimental insights to maximize reproducibility using APExBIO's high-purity Ellagic acid.

• Cannabis Terpenes Relieve Neuropathic Pain via A2A Receptors

  2026-06-08

  Schwarz et al. reveal that specific terpenes from Cannabis sativa induce robust antinociception in mouse models of chronic neuropathic pain by activating adenosine A2A receptors, rather than engaging canonical cannabinoid pathways. This mechanistic insight positions terpenes as promising, non-rewarding analgesic candidates and clarifies their distinct pharmacology relative to cannabinoid system modulators.

• 2-Deoxy-D-glucose: Applied Glycolysis Inhibition Workflows

  2026-06-08

  2-Deoxy-D-glucose (2-DG) from APExBIO enables precision glycolysis inhibition for advanced cancer metabolism and antiviral research. Discover actionable protocols, troubleshooting solutions, and new insights connecting metabolic stressors to cytoskeletal regulation.

• HyperScript RT SuperMix for qPCR: Precision in Gene Expressi

  2026-06-07

  The HyperScript RT SuperMix for qPCR streamlines cDNA synthesis, especially for gene expression studies involving low-abundance or structurally complex RNAs. Its advanced formulation delivers robust, reproducible results, empowering cancer biomarker discovery and translational research.

• Macrophage CCL7 Drives Immunotherapy Resistance in Colorecta

  2026-06-06

  The reference study uncovers how CCL7-expressing tumor-associated macrophages (TAMs) mediate resistance to immune checkpoint inhibitors in colorectal cancer. Mechanistic insights reveal that targeting CCL7 can enhance CD8+ T cell infiltration and improve the efficacy of immunotherapy, highlighting a novel axis for translational intervention.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Te

  2026-06-05

  DiI (DiIC18(3)) enables robust, high-contrast plasma membrane labeling for cell biology, neuronal tracing, and membrane-specific assays in both live and fixed samples. It is not suited for aqueous-only protocols or organelle targeting. This article outlines practical protocols, quality control, and troubleshooting for reproducible use.

• Actinomycin D: Precision Transcriptional Control in Translat

  2026-06-05

  Discover how Actinomycin D’s unique mechanistic properties empower translational researchers to dissect transcriptional stress, apoptosis, and mRNA dynamics in disease models. Drawing on recent cardiovascular discoveries, we explore strategic applications, protocol guidance, and the evolving landscape of transcriptional inhibition in both cancer and vascular biology.

• HyperScribe SP6 Kit: Enabling Next-Gen RNA Immunity Research

  2026-06-04

  Explore how the HyperScribe SP6 High Yield RNA Synthesis Kit drives high-fidelity RNA synthesis for advanced immunity studies. This article uniquely bridges mechanistic virology insights and practical assay design.

• RBMS1 Loss Enhances PD-L1 Blockade Response in TNBC Models

  2026-06-04

  The reference study uncovers RBMS1 as a post-transcriptional regulator of PD-L1 in triple-negative breast cancer (TNBC), showing that RBMS1 depletion sensitizes immune-cold tumors to checkpoint blockade. These findings highlight a new strategy to improve immunotherapy outcomes in TNBC by targeting RNA-binding protein-mediated immune evasion.

• Annexin V-FITC/7-AAD Apoptosis Kit: Technical Application Gu

  2026-06-03

  The Annexin V-FITC/7-AAD Apoptosis Kit enables rapid, sensitive discrimination of apoptotic and necrotic cells, streamlining standard cell viability and cytotoxicity assays. It is best suited for use with flow cytometry or fluorescence microscopy in conventional research workflows. This kit is not recommended for mechanistic pathway studies or unconventional cell death investigations.

• Probenecid as a Precision Tool for Immunometabolism and Neur

  2026-06-03

  Explore Probenecid’s unique role as a 4-(dipropylsulfamoyl)benzoic acid-based modulator in immunometabolic research and neuroprotection. This article provides a deeper analysis of its mechanisms and assay impact beyond multidrug resistance.

• 5-HT3 Antagonists Inhibit Renal OCT2 and MATE1 Transporters

  2026-06-02

  This study reveals that 5-HT3 receptor antagonists, including tropisetron, can inhibit the renal organic cation transporters OCT2 and MATE1 in vitro, with potential implications for drug-drug interactions and pharmacokinetics. The findings inform both mechanistic research and experimental assay design in transporter-mediated secretion.

• Actinomycin D in Translational Research: Mechanisms to Impac

  2026-06-02

  This thought-leadership article examines Actinomycin D (ActD) as an essential tool for translational researchers. We explore mechanistic insights into DNA intercalation and transcriptional inhibition, contextualize recent findings on transcriptional stress and cellular responses, and offer strategic guidance for deploying ActD in advanced molecular workflows. Drawing on both foundational principles and emerging research—including the interplay between phase separation, ER stress, and gene regulation—we position APExBIO’s Actinomycin D as a benchmark compound for dissecting apoptosis, mRNA stability, and the DNA damage response in cancer and beyond.

• Urolithin A in Precision Mitochondrial Research: Mechanisms

  2026-06-01

  Explore how Urolithin A, a gut microbiota-derived metabolite, is advancing mitochondrial biogenesis research and skeletal muscle gene modulation. This article uniquely connects mechanistic insights with actionable protocols and the latest reference breakthroughs.

16037 records 1/1070 page Next 12345 下5页 Last page